Innate Pharma (IPHYF) Shares Outstanding (Weighted Average) (2017 - 2025)

Innate Pharma's Shares Outstanding (Weighted Average) history spans 9 years, with the latest figure at $109.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 21.78% year-over-year to $109.1 million; the TTM value through Dec 2025 reached $109.1 million, up 21.78%, while the annual FY2025 figure was $109.1 million, 20.24% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $109.1 million in Q4 2025 per IPHYF's latest filing, up from $89.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $109.1 million in Q4 2025 to a low of $4.4 million in Q4 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $75.2 million, with a median of $89.6 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 527621.44% in 2021, then tumbled 94.68% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $91.0 million in 2021, then fell by 10.06% to $81.8 million in 2022, then crashed by 94.68% to $4.4 million in 2023, then soared by 1958.81% to $89.6 million in 2024, then increased by 21.78% to $109.1 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Shares Outstanding (Weighted Average) are $109.1 million (Q4 2025), $89.6 million (Q4 2024), and $4.4 million (Q4 2023).